News

Scientists have identified molecules that enable them to study and manipulate a specific type of cell present in the central nervous system, called glial cells, at the junctions where nerve cells communicate with muscles. Understanding how these cells operate at such sites, called neuromuscular junctions or synapses, has…

A research project underway at the University of Rhode Island (URI) aims to help people with advanced amyotrophic lateral sclerosis (ALS) and other severely limiting disorders communicate better by interacting with a computer that can translate their thoughts. Among the consequences of motor diseases like ALS is the…

Distinct RNA patterns in a person’s blood may signal the presence of amyotrophic lateral sclerosis (ALS), a study reports. Researchers, led by Majid Hafezparast, PhD, a professor of molecular neuroscience at the University of Sussex in the U.K., discovered that certain types of non-coding RNA (ncRNA), a…

Three Canadian provinces — Ontario, New Brunswick, and Alberta — have added Radicava (edaravone), a treatment for with amyotrophic lateral sclerosis (ALS), to their provincial medication plans. These recent but separate actions mean that Mitsubishi Tanabe Pharma’s intravenous infusion therapy is now listed on each province’s individual public…

Amyotrophic lateral sclerosis (ALS) patients who never regularly engaged in sports or physical activity have more extensive metabolic changes in the brain that likely help them to better cope with the disease’s neurodegenerative processes, a study from Europe suggests. These changes can reflect either greater metabolic activity in a…

The levels of certain indicators of iron status, namely ferritin and transferrin, are altered in patients with amyotrophic lateral sclerosis (ALS) relative to healthy controls, suggesting a possible link between iron metabolism and ALS, a study has found. The results, “Abnormal Serum Iron-Status Indicator Changes in…

The National Institutes of Health (NIH) is investing $25 million over five years in a program to encourage innovative research that deepens our understanding of  amyotrophic lateral sclerosis (ALS), with a goal of better treating the disease. Called Accelerating Leading-edge Science in ALS (ALS2), the initiative aims at…